Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01931033 · ClinicalTrials.gov registry record · NA

An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders

A NA study of Autism Spectrum Disorders and ASD, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT01931033: Completed NA study of Autism Spectrum Disorders and ASD, sponsored by Massachusetts General Hospital.

NCT01931033 is a NA study of Autism Spectrum Disorders and ASD that has completed, run by Massachusetts General Hospital. The registered enrollment target is 8 participants, below the 168-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01931033, a NA study of Autism Spectrum Disorders and ASD, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectrum disorders in adolescents ages 11-17.

Primary Outcome

Change in ASD symptoms as measured by change from baseline on the Social Responsiveness Scale 2 (SRS-2) scale. The SRS-2 is a 65-item rating scale completed that is used to measure the severity of autism spectrum symptoms as they occur in natural settings. The SRS-2 School Age form is completed by a parent or guardian for patients ages 9-17 and the SRS-2 Adult Self-report is completed by patients ages 18-59. Total raw scores range from 0 to 195, with higher scores indicating increased symptom s

Conditions Studied

Autism Spectrum Disorders ASD PDD Pervasive Developmental Disorders

Interventions

  • DRUG Intranasal Oxytocin

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2013-10
Est. Completion 2016-02-22
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT01931033 record still lists

NCT01931033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 168-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (95% lower).

The record links to 4 conditions, with Autism Spectrum Disorders appearing as the primary indexed condition, and to 1 intervention - of which Intranasal Oxytocin is the first listed.

NCT01931033 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01931033 about?

NCT01931033 is a clinical study titled "An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders". This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectr...

What is the current status of trial NCT01931033?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2013-10. Estimated completion is 2016-02-22.

What conditions does trial NCT01931033 study?

This clinical trial studies the following conditions: Autism Spectrum Disorders, ASD, PDD, Pervasive Developmental Disorders.

What interventions are being tested in trial NCT01931033?

The interventions under investigation include: Intranasal Oxytocin (DRUG).

Who is sponsoring clinical trial NCT01931033?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01931033 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Autism Spectrum Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01931033's enrollment target sits among peer trials

8 20th of 20 the lowest of 20 other Autism Spectrum Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01931033, the US trial registry maintained by the National Library of Medicine. NCT01931033 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.